The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for ...

The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...

ScPharmaceuticals, Inc. (SCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) today and set a price target of $25.00.Discover ...

Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...

Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of scPharmaceuticals in a ...

Rhumbline Advisers’ holdings in scPharmaceuticals were worth $151,000 at the end of the most recent quarter. Several other hedge funds have also made changes to their positions in SCPH.

But that doesn't mean long term investors can avoid big losses. To wit, the scPharmaceuticals Inc. (NASDAQ:SCPH) share price managed to fall 68% over five long years. That is extremely sub-optimal ...

A webcast of the presentations can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com .

Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization FDA approves scPharmaceuticals' expanded Furoscix indication ...